Skip to main content
OpenTrials
Enrolling by Invitation

NCT Number: NCT07723352

Journavx to Treat Pain After Thumb Basal Joint Arthroplasty

The purpose of this study is to find out how well suzetrigine, a newly FDA-approved non-opioid pain medication, works to relieve pain after thumb basal joint replacement surgery. The researchers believe that suzetrigine may provide effective pain relief during recovery without the use of opioid medications.

Enrolling by Invitation

Interested in participating?

Request Info

Key information

Conditions

Thumb Basal Joint Osteoarthritis Joint Replacement Joint Replacement Surgery Neurologic Manifestations Pain Pain, Postoperative Pathologic Processes Pathological Conditions, Signs and Symptoms Postoperative Complications Postoperative Pain Signs and Symptoms

Age range

40 year–80 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Rothman Orthopaedic Institute

Philadelphia, Pennsylvania, 19107, United States

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Aged 40-80 years.
  • Undergoing thumb basal joint arthroplasty (BJA)
  • Able to provide informed consent.
  • Willing to comply with the study procedures.

Exclusion criteria

  • History of substance abuse or chronic opioid use.
  • Known allergies to acetaminophen, oxycodone, or suzetrigine.
  • Severe renal or hepatic dysfunction
  • Estimated glomerular filtration rate less than 15 ml/min/1.73m^2
  • History of kidney transplant
  • Child-Pugh Class C
  • History of liver failure
  • Active hepatitis that can adversely influence hepatic function
  • Has had prior surgery on the study hand within the last 6 months
  • Is currently pregnant, planning to be pregnant, or breastfeeding
  • Use of strong or moderate CYP3A inhibitors or inducers, or medications known to interact with suzetrigine
  • Currently using a prescription pain medication other study medications

Treatment and study plan

suzetrigine 100mg

Drug

Participants will receive the recommended dosing for suzetrigine, which consists of a 100 mg oral loading dose taken in the recovery room prior to discharge, followed by 50 mg doses taken orally every 12 hours for 5 days, totaling 11 doses.

Acetaminophen

Drug

As part of the multimodal pain regimen, participants will also receive acetaminophen (Tylenol) (500 mg, every 4 hours, or 1000 mg, every 8 hours)

Primary outcomes

  1. Postoperative pain

    Time frame: 5 days

    Participants Pain will be assessed using the Numeric Rating Scale (NRS)at regular daily postoperative intervals

Sponsors and collaborators

Lead sponsor

Rothman Institute Orthopaedics

Other

Registry information

Official study title

A Single-Arm Open-Label Trial Evaluating the Efficacy of Suzetrigine (Journavx) in Multimodal Postoperative Pain Management Following Thumb Basal Joint Arthroplasty

Important dates

Study start
2026
Primary completion
2028
Study completion
2028
First posted
Jul 23, 2026
Registry last updated
Jul 23, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.